Menu
Enrolling by invitation NCT07074093

Effect of an App-based Intervention on Air Pollution in COPD Patients

No phase Interventional COPD (Chronic Obstructive Pulmonary Disease)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: app+smartband+education.
Who it may be relevant to
Registry conditions: COPD (Chronic Obstructive Pulmonary Disease). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of an Educational Intervention and an App-based Outdoor Air Pollution Alert System on Reducing Exacerbations in COPD Patients

Overview

This study will test whether a combination of health education, a mobile app, and a smart band can help people with chronic obstructive pulmonary disease (COPD) improve their quality of life and reduce flare-ups. Participants will be randomly assigned to one of two groups: One group will receive health education, use a mobile app that shows real-time air quality (AirVisual), and wear a smart band that tracks activity and sleep (Amazfit Band 5). The other group will receive standard care and advice. All participants will complete health checks and quality-of-life questionnaires at the beginning of the study and again after 6 months. The goal is to find out if this combination of tools helps people with COPD manage their condition better and have fewer flare-ups.

Detailed description

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that makes it hard to breathe and often gets worse over time. Many people with COPD experience flare-ups, which are periods when symptoms suddenly get worse. These flare-ups can be triggered by poor air quality and may lead to hospital visits or reduced quality of life.

This study will test a non-drug approach to help people with COPD manage their condition better. The researchers want to find out if using a combination of tools-health education, a mobile app, and a smart band-can reduce the number of flare-ups and improve quality of life.

The mobile app (AirVisual) provides real-time information about outdoor air quality, which may help participants avoid pollution. The smart band (Amazfit Band 5) tracks physical activity and sleep, helping users stay active and monitor their health. Participants in the intervention group will be trained on how to use both tools and receive general education about COPD management. The control group will receive standard care and advice.

A total of 150 participants will be recruited from urban health centers in Salamanca, Spain. Participants will be randomly assigned to either the intervention or control group. The study will last 6 months. All participants will have a clinical visit at the beginning and at the end of the study, where health measurements and quality-of-life questionnaires will be completed.

The goal is to learn whether this digital, non-pharmacological approach can support better daily management of COPD and lead to fewer symptom flare-ups.

Interventions

  • Combination product app+smartband+education
    Intervention: Behavioral: Health education Device: AirVisual App Device: Amazfit Band 5

Primary outcome measures

  • Number of COPD exacerbations [Time frame: From baseline to 6 months]
Secondary outcome measures (7)
  • Change in health-related quality of life [Time frame: Baseline and 6 months]
  • Change in Physical Activity Level [Time frame: Baseline to 6 months]
  • Change in BODE Index Score [Time frame: Baseline and 6 months]
  • Change in Blood Pressure [Time frame: Baseline and 6 months]
  • Change in Lipid profile [Time frame: Baseline and 6 months]
  • Healthcare Resource Use [Time frame: 12 months before and 6 months after the intervention]
  • Change in HbA1c [Time frame: Baseline and 6 months]

Eligibility criteria

Inclusion criteria

Male or female, aged 18 years or older

Clinical diagnosis of chronic obstructive pulmonary disease (COPD) based on GOLD 2022 criteria (post-bronchodilator FEV1/FVC < 0.70)

Receiving care at urban primary care centers in Salamanca, Spain

Able to use a smartphone (independently or with minimal assistance)

Able and willing to provide written informed consent

Exclusion criteria

Diagnosis of a respiratory disease other than COPD (e.g., asthma, interstitial lung disease)

Moderate to severe cognitive impairment

Significant physical limitation that prevents participation in physical activity (e.g., NYHA Class III or IV heart failure, musculoskeletal conditions limiting walking)

Advanced kidney or liver disease

Severe mental illness or terminal condition

Participation in another clinical trial

Inability to use the mobile phone or smart band due to physical or technological limitations

Plans to relocate to another city within 12 months of study start

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Spain · 1 center
  • Unidad de Investigación de AP de Salamanca — Salamanca

Publications

  • Vicente-Garcia T, Maderuelo-Fernandez JA, Marcos-Romero I, Herrero-Hernandez B, Conde-Martin S, Rodriguez-Sanchez E, Gomez-Marcos MA, Garcia-Ortiz L, Lugones-Sanchez C. The effect of an educational intervention and an app-based outdoor air pollution alert system in reducing exacerbations in patients with COPD. BMC Prim Care. 2025 Dec 1;27(1):4. doi: 10.1186/s12875-025-03109-0. PMID 41327038

Identifiers

NCT: NCT07074093 · GRS 2519/B/22

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗